Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioventix Regulatory News (BVXP)

Share Price Information for Bioventix (BVXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,450.00
Bid: 4,400.00
Ask: 4,500.00
Change: 0.00 (0.00%)
Spread: 100.00 (2.273%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4,450.00
BVXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of CFO

1 Jul 2020 07:00

Bioventix Plc - Appointment of CFO

Bioventix Plc - Appointment of CFO

PR Newswire

London, June 30

Bioventix plc(“Bioventix” or the “Company”)

Appointment of CFO

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that Bruce Hiscock will join the Board as Chief Financial Officer with immediate effect.

Mr Hiscock was previously CEO and CFO of everyLIFE Technologies, a technology business delivering digital care planning solutions to social care providers. Prior to this he was the Managing Director of MITIE Security Systems, the CEO of Protec plc, an AIM listed security and technology services business, and held several CFO roles at both fast-growing listed and private companies over a 30-year career. Mr Hiscock is a member of the Institute of Chartered Accountants of Scotland.

The following information regarding the appointment of Bruce Edward Heath Hiscock (aged 61) is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies:

Current directorships and/or partnershipsFormer directorships and/or partnerships (within the last five years)
n/aeveryLIFE Technologies Limited Warnborough Associates Limited

There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.

For further information please contact:

Bioventix plc Peter Harrison Chief Executive OfficerTel: 01252 728 001
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane Corporate Finance ECMTel: 020 7220 0500

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

Date   Source Headline
25th Mar 20247:00 amRNSInterim Results
29th Jan 20243:15 pmRNSDirector/PDMR Shareholding
7th Dec 20233:26 pmRNSResult of AGM
28th Nov 20233:26 pmRNSDirector/PDMR Shareholding
16th Nov 202312:40 pmRNSHolding(s) in Company
10th Nov 20234:23 pmRNSPosting of Annual Report and Notice of AGM
7th Nov 202312:07 pmRNSHolding(s) in Company
1st Nov 20234:07 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSResults for the year ended 30 June 2023
25th Sep 20234:28 pmRNSHolding(s) in Company
19th Sep 20232:29 pmRNSHolding(s) in Company
24th Jul 20237:00 amRNSHolding(s) in Company
6th Jul 20232:48 pmRNSHolding(s) in Company
30th May 20237:00 amRNSBoard Appointment
19th May 20237:00 amRNSDirector/PDMR Shareholdings and Issue of Equity
25th Apr 202310:35 amRNSDirector/PDMR Shareholding
11th Apr 20232:45 pmRNSHolding(s) in Company
31st Mar 20232:45 pmRNSDirector/PDMR Shareholding
27th Mar 20237:00 amRNSInterim Statement
8th Mar 20235:50 pmRNSHolding(s) in Company
31st Jan 20235:03 pmRNSDirector/PDMR Shareholding
25th Jan 20233:23 pmRNSHolding(s) in Company
29th Mar 20227:00 amPRNInterim Dividend Confirmation
28th Mar 20227:00 amPRNHalf-year Report
9th Dec 20213:41 pmPRNResult of AGM
22nd Nov 20213:25 pmPRNDirector/PDMR Shareholding
11th Nov 20212:32 pmPRNPosting of Annual Report and Notice of AGM
25th Oct 20216:15 pmPRNHolding(s) in Company
18th Oct 20212:41 pmPRNDirector/PDMR Shareholding
18th Oct 20217:00 amPRNResults for the year ended 30 June 2021
31st Aug 202111:07 amPRNHolding(s) in Company
11th Aug 20212:41 pmPRNHolding(s) in Company
21st Jul 20214:27 pmPRNHolding(s) in Company
8th Jun 202111:17 amPRNHolding(s) in Company
8th Jun 202111:17 amPRNHolding(s) in Company
29th Mar 20217:00 amPRNHalf-year Report
25th Feb 20214:35 pmRNSPrice Monitoring Extension
10th Dec 20203:03 pmPRNResult of AGM
16th Nov 20202:16 pmPRNPosting of Annual Report and Notice of AGM
27th Oct 20205:27 pmPRNHolding(s) in Company
19th Oct 20207:00 amPRNResults for the year ended 30 June 2020
20th Aug 202012:37 pmPRNHolding(s) in Company
8th Jul 20207:00 amPRNIssue of Equity
1st Jul 20207:00 amPRNAppointment of CFO
1st Jul 20207:00 amPRNAppointment of CFO
2nd Apr 20202:21 pmPRNDirector/PDMR Shareholding
31st Mar 20205:47 pmPRNCorrection : Interim Results
30th Mar 20202:06 pmRNSSecond Price Monitoring Extn
30th Mar 20202:01 pmRNSPrice Monitoring Extension
30th Mar 202011:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.